retatrutide type 2 diabetes trial results 2024 phase 2 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Phase III retatrutide study demonstrates

The green dye PVP MNs were affixed to an applicator and applied to the prepared area of the skin

Total testosterone might drop, but if SHBG drops more, your biologically active free testosterone could actually be stable or even increase

Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers

DePetrocellis LVellaniVSchiano-MorielloAMariniPMagheriniPCOrlandoPet al

Always take weight loss medication under medical supervision to keep treatment safe

J Hypertens 1999;17:457-63